Evidence map›Paper›PMID 24675761›Full record

ArticlePLoS pathogens2014

Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV.

Christopher Chiu, Megan McCausland, John Sidney, Fuh-Mei Duh, Nadine Rouphael, Aneesh Mehta, Mark Mulligan, Mary Carrington, Andreas Wieland, Nicole L Sullivan and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. The ageing immune system and its battle with viruses.The Journal of general virology · 2026
    Review
  5. Varicella zoster virus and the central nervous system.Nature reviews. Microbiology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. A Simple-to-PerformFrontiers in immunology · 2022
    Article
  17. Review
  18. Upregulation of Multiple CD8Journal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  19. Review
  20. Characterization of Virus-specific Immune Response During Varicella Zoster Virus Encephalitis in a Young Adult.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Christopher ChiuEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America; Centre for Respiratory Infection, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Megan McCauslandEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, United States of America.
Fuh-Mei DuhCancer and Inflammation Program, Laboratory for Experimental Immunology, SAIC Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Nadine RouphaelHope Clinic of the Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America; Division of Infectious Diseases School of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Aneesh MehtaDivision of Infectious Diseases School of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Mark MulliganHope Clinic of the Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America; Division of Infectious Diseases School of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Mary CarringtonCancer and Inflammation Program, Laboratory for Experimental Immunology, SAIC Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Andreas WielandEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Nicole L SullivanEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Adriana WeinbergDepartments of Pediatrics, Medicine and Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
Myron J LevinDepartments of Pediatrics, Medicine and Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
Bali PulendranEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, United States of America.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, United States of America.
Rafi AhmedEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Emory University · USLa Jolla Institute for Immunology · USFrederick National Laboratory for Cancer Research · USUniversity of Colorado Anschutz Medical Campus · USHOPE Clinic · USImperial College London · GB

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7M
Systems Biological Analysis of Innate and Adaptive Responses to VaccinationU19AI090023 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, LI, SHUZHAO · 2010 to 2021
$45.0M
Effects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2M
CCR NIH HHS HHSN261200800001CIntramural NIH HHSMedical Research Council G0902266Medical Research Council G1000758NCI NIH HHS HHSN261200800001ENIAID NIH HHS U19 AI05726NIAID NIH HHS U19 AI057266NIAID NIH HHS U19 AI090023-01NIH HHS P51 OD011132
6 · The paper itself

Abstract

Human herpesviruses are important causes of potentially severe chronic infections for which T cells are believed to be necessary for control. In order to examine the role of virus-specific CD8 T cells against Varicella Zoster Virus (VZV), we generated a comprehensive panel of potential epitopes predicted in silico and screened for T cell responses in healthy VZV seropositive donors. We identified a dominant HLA-A*0201-restricted epitope in the VZV ribonucleotide reductase subunit 2 and used a tetramer to analyze the phenotype and function of epitope-specific CD8 T cells. Interestingly, CD8 T cells responding to this VZV epitope also recognized homologous epitopes, not only in the other α-herpesviruses, HSV-1 and HSV-2, but also the γ-herpesvirus, EBV. Responses against these epitopes did not depend on previous infection with the originating virus, thus indicating the cross-reactive nature of this T cell population. Between individuals, the cells demonstrated marked phenotypic heterogeneity. This was associated with differences in functional capacity related to increased inhibitory receptor expression (including PD-1) along with decreased expression of co-stimulatory molecules that potentially reflected their stimulation history. Vaccination with the live attenuated Zostavax vaccine did not efficiently stimulate a proliferative response in this epitope-specific population. Thus, we identified a human CD8 T cell epitope that is conserved in four clinically important herpesviruses but that was poorly boosted by the current adult VZV vaccine. We discuss the concept of a "pan-herpesvirus" vaccine that this discovery raises and the hurdles that may need to be overcome in order to achieve this.

Indexed as

AdultCD8-Positive T-LymphocytesCross ReactionsEnzyme-Linked Immunosorbent AssayEpitopes, T-LymphocyteFlow CytometryHerpesvirus 3, HumanHerpesvirus 4, HumanHerpes Zoster VaccineHLA-A2 AntigenHumansSimplexvirusViral VaccinesEpitopes, T-LymphocyteHerpes Zoster VaccineHLA-A*02:01 antigenHLA-A2 AntigenViral Vaccines

Identifiers

PMID24675761
PMCPMC3968128
OpenAlexW2005706092

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.